Investor Presentaiton

• • Eurofins at the forefront of innovation with new COVID-19 related developments * eurofins • Two important milestones reached: • ○ 25m+ COVID-19 PCR tests completed since the start of the pandemic О 125,000+ SARS-CoV-2 samples from 23 countries sequenced since its press release on 28th December 2020 announcing the launch of a new ARTIC Next Generation Sequencing (NGS) service Clinical Enterprise awarded U.S. Government agreement¹ to provide national COVID-19 testing opportunities to 24m+ people in K-8 schools, underserved populations and congregate settings such as homeless shelters Eurofins Viracor launched new tests, including COVID-19 SARS-CoV-2 inSIGHT TM T Cell Immunity Testing to support healthcare providers with the supply of critical insights to aid in treatment decisions Eurofins Genomics launched SynPure Linear Polyacrylamide for COVID testing and other research and development applications Eurofins Technologies continued to develop diagnostic solutions for COVID-19, particularly in response to emerging mutations: GSD NovaType III SARS-CoV-2 RT-PCR assay for the rapid, one-step detection of SARS-CoV-2 Variants of Concern о Upgrade of COVID wastewater testing capabilities with variant detection capabilities EmpowerDX direct-to-consumer, FDA-authorised COVID-19 Home Collection PCR kit were launched on Amazon U.S. and in all Rite Aid stores across 17 states in the U.S. EmpowerDX first to receive FDA-emergency use authorization for its at-home nasal PCR test for children three years and older 1 Agreement available at https://www.defense.gov/Newsroom/Releases/Release/Article/2633565/memorandum-of-understanding-for-acquisition-support-signed-between-the-departme/ eurofins eurofins 26

View entire presentation